The full 3rd US Circuit Court of Appeals on Monday, October 21, declined to reconsider a ruling that forced into arbitration an antitrust case by a drug wholesaler accusing Johnson & Johnson of suppressing competition for its blockbuster rheumatoid arthritis drug Remicade, reported Reuters.
The ruling, issued on September 13 by a three-judge panel, had overturned a 2018 decision by US District Judge Curtis Joyner in Philadelphia by holding that a broadly worded arbitration clause contained in the drug distribution contract Rochester Drug Cooperative (RDC) had with J&J covered its claims.
In its complaint, filed in 2018, RDC noted that, despite competition from biosimilars, J&J’s brand-name infliximab maintained and even increased its prices. “J&J did not achieve this unusual result by competition on the merits,” stated the complaint, “but instead through a multifaceted scheme to block biosimilar competition to Remicade through a web of exclusive dealing contracts.”
This case is just one of multiple cases related to J&J’s strategy to defend its market share for infliximab. In 2017, Pfizer filed an antitrust suit against J&J, alleging that the drug maker’s tactics had effectively denied patients access to biosimilar therapies (including Pfizer’s Inflectra) and undermined price competition in the biologics marketplace.
Full Content:
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI